Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma.
Ian F ParneyS Keith AndersonMichael P GustafsonSusan SteinmetzTimothy E PetersonTrynda N KronemanAditya RaghunathanBrian P O'NeillJan C BucknerMary SolsethAllan B DietzPublished in: Neuro-oncology advances (2022)
This vaccine platform is safe and highly feasible in combination with standard therapy for newly diagnosed patients. Imaging, histological, survival, and immunological data suggest a positive biological response to therapy that warrants further investigation.
Keyphrases
- newly diagnosed
- dendritic cells
- bone marrow
- stem cell transplantation
- end stage renal disease
- high resolution
- clinical trial
- chronic kidney disease
- electronic health record
- study protocol
- regulatory t cells
- ejection fraction
- immune response
- big data
- machine learning
- prognostic factors
- high dose
- free survival
- data analysis
- single cell
- artificial intelligence
- platelet rich plasma
- fluorescence imaging